Lung cancer is the leading cause of cancer-related
|
|
- Lawrence Blankenship
- 5 years ago
- Views:
Transcription
1 Original Articles Correlation of Mutation Status With Predominant Histologic Subtype of Adenocarcinoma According to the New Lung Adenocarcinoma Classification of the International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Celina Villa, MD; Philip T. Cagle, MD; Melissa Johnson, MD; Jyoti D. Patel, MD; Anjana V. Yeldandi, MD; Rishi Raj, MD; Malcolm M. DeCamp, MD; Kirtee Raparia, MD Context. Epidermal growth factor receptor () mutations have been identified as predictors of response to tyrosine kinase inhibitors in non small cell lung cancer. Objective. To investigate the relationship of mutation status to the histologic subtype of adenocarcinoma according to the new International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification. Design. We screened mutation in 200 consecutive lung adenocarcinoma resection specimens diagnosed between 2008 and Results. Among 200 lung adenocarcinomas, mutations were identified in 41 tumors (20.5%). The mean age in the -mutant group was 64.8 years and this group consisted of 78% females and 22% males. Most patients with -positive lung cancers were never-smokers (51%) as compared to 8% with -negative cancers (P,.001). Lung cancer is the leading cause of cancer-related mortality in both men and women in the United States. It is projected that in 2013, lung cancer will account for 26% and 28% of cancer-related deaths in the female and male populations, respectively. 1 Historically, lung cancer has been Accepted for publication December 27, Published as an Early Online Release February 26, From the Department of Pathology (Drs Villa, Yeldandi, and Raparia), the Division of Medical Oncology, and Robert H. Lurie Comprehensive Cancer Center (Drs Johnson and Patel), the Division of Pulmonary, and Critical Care Medicine (Dr Raj); and the Division of Thoracic Surgery, and Robert H. Lurie Comprehensive Cancer Center (Dr DeCamp), Northwestern University Feinberg School of Medicine, Chicago, Illinois; and the Department of Pathology & Genomic Medicine, The Methodist Hospital, Houston, Texas (Dr Cagle). The authors have no relevant financial interest in the products or companies described in this article. The study was presented at the United States and Canadian Academy of Pathology 2012; March 17 23, 2012; Vancouver, British Columbia, Canada. Reprints: Kirtee Raparia, MD, Department of Pathology, 303 East Chicago Avenue, Northwestern University Feinberg School of Medicine, Chicago, IL ( kraparia@northwestern.edu). The most common mutations identified in our population were deletions in exon 19 (22 patients) and L858R in exon 21 (12 patients). Five patients had double mutations. The predominant pattern of adenocarcinoma was lepidic (44%) in -mutant lung cancers as compared to 69% with acinar pattern in wild-type lung cancers (P,.001). Of 22 minimally invasive adenocarcinomas, 8 (36%) had mutations, accounting for 20% of adenocarcinomas with mutations (P,.05). Conclusions. Based on the new IASLC/ATS/ERS classification, the predominant subtype of adenocarcinoma was lepidic (44%) in -mutant lung cancers (P,.001). However, histologic subtype should not be used to exclude patients from tyrosine kinase inhibitor therapy, since mutations are found in lung adenocarcinomas of other subtypes. (Arch Pathol Lab Med. 2014;138: ; doi: /arpa OA) divided into 2 major categories by histologic feature and response to conventional therapies: non small cell lung carcinoma (NSCLC) and small cell lung carcinoma. NSCLC includes 3 major cell types (adenocarcinoma, squamous cell carcinoma, and large cell carcinoma), and these can be further divided into various subtypes or variants. 2 NSCLC accounts for most (~85%) of the lung cancers, with lung adenocarcinoma being the most common subtype in the Western population. Recently the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) proposed an international multidisciplinary lung adenocarcinoma classification. This system divides adenocarcinoma into adenocarcinoma in situ (5-year survival: 100%), minimally invasive adenocarcinoma (5-year survival: 100%), and invasive adenocarcinoma. Invasive adenocarcinoma includes lepidic, acinar, papillary, micropapillary, and solid predominant patterns and mucinous, colloid, fetal, and enteric variants. 3 Development of invasive lung carcinoma is a result of sequential accumulation of genetic and epigenetic changes that are also reflected in the morphology of these tumors. Arch Pathol Lab Med Vol 138, October 2014 Mutation and Survival in Lung Adenocarcinoma Villa et al 1353
2 Lung cancer is now considered a heterogeneous group of diseases, and mutational profilingoflungadenocarcinoma is a routine practice in thoracic oncology. The discovery of activating mutations in the epidermal growth factor receptor () of lung adenocarcinoma tumors, and the subsequent recognition that this biomarker predicted high response rates and prolonged progression-free survival after treatment with tyrosine kinase inhibitors (TKIs), led to a dramatic revolution in the treatment of patients with lung cancer. 4 7 The College of American Pathologists (CAP), the IASLC, and the Association for Molecular Pathology recently published evidence-based recommendations for the molecular testing of lung cancers for mutations that specify that testing should be performed for all patients with advanced-stage adenocarcinoma, regardless of sex, race, smoking history, or other clinical risk factors. 8 Although several studies published in the recent past correlate adenocarcinoma subtypes with mutations, we present the largest study to date of sequential pulmonary adenocarcinomas, correlating mutation status with the proposed IASLC/ATS/ERS adenocarcinoma classification in a Western population. MATERIALS AND METHODS The Institutional Review Board at the Northwestern University, Feinberg School of Medicine, Chicago, Illinois, approved the study. Patient Selection and Histologic Analysis Consecutive pulmonary adenocarcinomas obtained only from resection specimens and screened for mutations/deletions in exons 18, 19, 20, and 21 between the years 2008 and 2011 in the Department of Pathology, Northwestern Memorial Hospital (Chicago, Illinois), were included in the study. The staging of the lung cancers included stage I (n ¼ 132), stage 2 (n ¼ 24), stage 3(n¼31), and stage 4 (n ¼ 13) according to the 7th edition of AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 9 Clinical parameters, including smoking history, were collected from the medical records. Patients with smoking history of less than 20 pack-years were considered light smokers. 10 We classified all the adenocarcinomas according to the recent IASLC/ ATS/ERS international multidisciplinary lung adenocarcinoma classification. Molecular Analysis The mutational analysis was performed on DNA samples extracted from surgically resected specimens of lung adenocarcinomas by using polymerase chain reaction (PCR) and Qiagen PyroMark 24 sequencer (Qiagen, Valencia, California). Formalin-fixed, paraffin embedded blocks of tumor tissue (50 lm) were treated with Hemo-De (Scientific Safety Solvents, Keller, Texas) and then digested overnight at 568 in a Proteinase K and lysate solution. Genomic DNA was extracted from the digested lysate by using the Qiagen QIAsymphony DNA extractor. The Qiagen Pyro Kit provides quantitative measurements of mutations in the gene at codons, 719, 768, 790, 858, and 861, as well as deletions and complex mutations in exon 19. Ten nanograms of DNA were added to 4 separate PCR reactions using pyro-specific primers for codons 719, 768, and 790, , and exon 19). The 4 PCR products were then immobilized to Steptavidin Sepharose High-Performance beads (GE Healthcare Bio-Sciences, Pittsburgh, Pennsylvania) and added to 5 different pyrosequencing reactions (codons 719, 768, 790, , and exon 19). The products were purified on the PyroMark worktable and then added to the PyroMark Q24 pyrosequencer. The results were analyzed by using the Pyro- Mark Q24 software (Qiagen). 11 Statistical Analysis The relationships between gene mutation status and the clinicopathologic features, including subtype according to the IASLC/ATS/ERS proposed classification, were analyzed by using Fisher exact test for categorical variables and the Wilcoxon ranksum test for continuous variables. RESULTS Mutations and Demographics The frequency of mutations and no mutations (wild type) in 200 tumors was 20.5% and 79.5%, respectively. The mean age in the -mutant group was 64.8 years (age range, 39 to 86 years) and was similar to that of patients with wild-type tumors. As expected, mutations were more common in tumors sampled from female (78%) than male patients (22%). Most patients whose tumors had mutation were never-smokers (51%) as compared to 8% in patients with wild-type tumors (P,.001) (Figure 1; Table 1). Mutations and Histologic Subtypes Eight (36%) of 22 minimally invasive adenocarcinomas had mutations, representing 20% of the lung cancers with mutant gene as compared to 9% of the lung cancers with wild-type gene (P ¼.05) (Figure 2). The predominant pattern seen in the -mutant positive lung cancer group was lepidic (44%) as compared to patients with wild-type gene, whose tumors exhibited acinar pattern in 69% and lepidic pattern in 15% of cases; P,.001 (Figure 3). We also analyzed the histologic patterns in adenocarcinomas in relation to exon 19 deletions versus exon 21 mutations, and found no specific pattern associated with either of these specific mutations. The patient with T790M mutations had predominant acinar histologic pattern. Thyroid transcription factor 1 (TTF-1) positivity was seen in all the -mutant positive lung cancers tested (P ¼.05). The clinical and pathologic findings in both mutant and wild-type pulmonary adenocarcinomas are summarized in Table 2. Types of Mutations The mutations identified in our population were L858R in exon 21 (n ¼ 12 ), E746 deletions in exon 19 (n ¼ 12), L747 deletions in exon 19 (n ¼ 5), other deletions in exon 19 (n ¼ 5), G719A in exon 18 (n ¼ 2), S768 in exon 20 (n ¼ 2), L861Q mutation in exon 21 (n ¼ 4), T790M in exon 20 (n ¼ 1), and E709 in exon 18 (n ¼ 1). Five cancers had double mutation (Table 3). COMMENT Although there have been several studies in the recent past attempting to identify the histologic correlates of lung adenocarcinomas with mutations, the relationship between mutations and subtype of adenocarcinoma remains unclear. Studies suggest that mutations are found in 5% to 20% of white patients and 20% to 60% of Asian patients with lung adenocarcinomas Although mutations are frequently observed in never-smoker females with invasive adenocarcinoma having a predominant lepidic pattern, a significant percentage have also been noted in acinar and papillary variants of adenocarcinoma. 5,14,17,20 26 A study involving white patients identified that all the tumors with mutations were nonmucinous, well-differentiated, TTF-1 positive adenocarcinomas. 22 Rekhtman et al 27 also 1354 Arch Pathol Lab Med Vol 138, October 2014 Mutation and Survival in Lung Adenocarcinoma Villa et al
3 Table 1. Demographics of Patients With Mutant and Wild-Type Lung Cancers Characteristics Mutant Wild Type P Value Total patients, No. (%) 41 (20.5) 159 (79.5) Age, y Mean Median SD Range Age, No. (%) 65 y 17 (42) 71 (45) y 24 (58) 88 (55) Sex, No. (%) Male 9 (22) 50 (31).23 Female 32 (78) 109 (69) Smoking status, No. (%) Light smokers 10 (24) 26 (16),.001 Heavy smokers 10 (25) 120 (76) Never-smokers 21 (51) 13 (8) Follow-up duration, mo Mean Median SD Range Abbreviation:, epidermal growth factor receptor gene. Figure 1. Patients smoking history and mutation status: 56% of patients in the -mutant group were never-smokers as compared to 14% in the wild-type group; P,.001. Figure 2. Minimally invasive adenocarcinoma (MIA) and mutation status: MIA was seen in 8 -mutant lung cancers (36%) representing 20% of the lung cancers with mutant gene as compared to 9% of the lung cancers with wild-type gene; P ¼.05. showed that in a group of 35 patients (19%) who were positive for mutation and were never-/light smokers, the mutations were associated with nonmucinous adenocarcinoma with lepidic and papillary patterns that expressed TTF-1. A study in Chinese patients 25 showed that mutations were closely associated with the micropapillary and lepidic subtypes. Russell et al 23 showed that mutations were identified in 22% of patients with stage III (N2) lung adenocarcinoma and were associated with acinar and micropapillary predominant tumors. Our study similarly shows a 20.5% frequency of mutations, occurring commonly in females and never-smokers (51% of patients). The common mutations in lung adenocarcinoma in our series, L858R in exon 21 that was present in 12 patients (29%) and deletions in exon 19 (including E746 and L747) in 34 patients (54%), paralleled results from previous studies. In addition, 5 patients (12%) in our study had double mutations and 3 patients had rare exon 18 mutations. exon 21 mutations were commonly associated with lepidic predominant adenocarcinomas and exon 20 mutations with solid histology in the past studies. 28,29 But we did not find any association between the histologic patterns and tumors with exon 19 deletions versus exon 21 mutations. However, 1 patient with T790M mutation in our study had predominant acinar histologic pattern. Histologic features of lung adenocarcinoma may play a role in predicting the outcome in patients with mutation who are treated with TKIs. Yoshida et al 30 have shown that patients with mutations with predominant Figure 3. Predominant pattern of adenocarcinoma and mutation status: mutant-positive lung cancers were lepidic (44%) as compared to tumors with wild-type gene, whose tumors exhibited acinar pattern in 69% and lepidic pattern in 15%; P,.001. Arch Pathol Lab Med Vol 138, October 2014 Mutation and Survival in Lung Adenocarcinoma Villa et al 1355
4 Table 2. Clinical and Pathologic Characteristics of Mutant and Wild-Type Pulmonary Adenocarcinomas Characteristics Mutant, No. (%) Wild Type, No. (%) P Value Tumor size, cm,2 23 (56) 99 (62) (27) 24 (15) (15) 24 (15).5 1 (2) 12 (8) Predominant pattern Lepidic 18 (44) 23 (15),.001 Acinar 17 (42) 109 (69) Papillary 2 (5) 5 (3) Solid 3 (7) 20 (13) Micropapillary 0 0 Variants of adenocarcinoma Mucinous 1 (2) 2 (1).50 MIA Yes 8 (20) 14 (9).05 No 33 (80) 145 (91) TTF-1 positivity Positive 32 (100) 101 (89).05 Negative 0 (0) 12 (11) Pleural status PI present 5 (12) 29 (18).35 PI absent 36 (88) 130 (82) Nodal status N0 32 (84) 109 (78).52 N1 2 (5) 16 (11) N2 3 (8) 14 (10) N3 1 (3) 1 (1) Patients developing brain metastasis 2 (5) 13 (8).47 Abbreviations:, epidermal growth factor receptor gene; MIA, minimally invasive adenocarcinoma; PI, pleural invasion (visceral); TTF-1, thyroid transcription factor 1. solid pattern of adenocarcinoma have significantly worse overall response to TKIs. Others 17,23,31 have shown that the new classification correlates with patient prognosis and provides important prognostic information. Our study is the largest study of sequential pulmonary adenocarcinomas correlating mutation status with the Table 3. Types of Mutations in 41 Patients Positive for Mutations Mutation Exon No. of Patients G719A 18 2 E E746-A750 del L747- P753 del 19 3 L747-S752 del 19 1 L747-T751 del 19 1 Other deletions in exon T790M 20 1 S A767-V A767-Y L858R L861Q 21 4 Double mutation 5 proposed IASLC/ATS/ERS adenocarcinoma classification. Based on the proposed classification, adenocarcinomas with predominant lepidic pattern are more commonly associated with mutations (P,.001). However, subtype should not be used to exclude patients from TKI therapy, since mutations are found in lung adenocarcinomas of other subtypes. References 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer J Clin. 2013;63(1): Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARCPress; World Health Organization Classification of Tumours; vol Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2): Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36): Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21): Paez JG, Janne PA, Lee JC, et al. mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676): Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10): Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137(6): Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. Chicago, IL: Springer; Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006;24(11): Rho JK, Choi YJ, Lee JK, et al. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol Cancer Res. 2009;7(10): Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2): Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007;25(5): Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 2005;11(3): Li C, Sun Y, Fang Z, et al. Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma. J Thorac Oncol. 2011;6(6): Liam CK, Wahid MI, Rajadurai P, Cheah YK, Ng TS. Epidermal growth factor receptor mutations in lung adenocarcinoma in malaysian patients. J Thorac Oncol. 2013;8(6): Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ ERS lung adenocarcinoma classification for prognosis and association with and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013;8(1): Bauml J, Mick R, Zhang Y, et al. Frequency of and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer. 2013;81(3): Boch C, Kollmeier J, Roth A, et al. The frequency of and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open. 2013;3(4). 20. Sun PL, Seol H, Lee HJ, et al. High incidence of mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, /TTF-1 expressions, and clinical features. J Thorac Oncol. 2012;7(2): Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64(24): Leary AF, Castro DG, Nicholson AG, et al. Establishing an mutation screening service for non-small cell lung cancer sample quality criteria and candidate histological predictors. Eur J Cancer. 2012;48(1): Russell PA, Barnett SA, Walkiewicz M, et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol. 2013;8(4): Mazieres J, Rouquette I, Lepage B, et al. Specificities of lung adenocarcinoma in women who have never smoked. J Thorac Oncol. 2013;8(7): Arch Pathol Lab Med Vol 138, October 2014 Mutation and Survival in Lung Adenocarcinoma Villa et al
5 25. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Correlation of mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol. 2013;30(3): Shim HS, Lee da H, Park EJ, Kim SH. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med. 2011;135(10): Rekhtman N, Ang DC, Riely GJ, Ladanyi M, Moreira AL. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol. 2013;26(10): Lee HJ, Kim YT, Kang CH, et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology. 2013;268(1): Arcila ME, Nafa K, Chaft JE, et al. exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2): Yoshida T, Ishii G, Goto K, et al. Solid predominant histology predicts tyrosine kinase inhibitor response in patients with mutation-positive lung adenocarcinoma. J Cancer Res Clin Oncol. 2013;139(10): Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013;81(3): Arch Pathol Lab Med Vol 138, October 2014 Mutation and Survival in Lung Adenocarcinoma Villa et al 1357
THE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS
THE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS PULMONARY PATHOLOGY SOCIETY USCAP, BALTIMORE, March 2, 2013 William D. Travis, M.D. Dept of Pathology, Memorial Sloan-Kettering Cancer
More informationApplying Genomics to Cancer 21 st September The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience
Applying Genomics to Cancer 21 st September 2015 The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience Aled Daniels R Butler, R Attanoos, H Davies University Hospital of Wales
More informationPrudence Anne Russell 1,2, Gavin Michael Wright 3,4
Editorial Page 1 of 7 Predominant histologic subtype in lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients: discovery of a holy grail? Prudence Anne Russell
More informationEGFR, Lung Cancer and Cytology. Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan.
EGFR, Lung Cancer and Cytology Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan. It is histopathologically divided into two major sub-groups: Small
More informationLung cancer is now a major cause of death in developed
Original Article New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma Naoki Yanagawa, MD, PhD,* Satoshi Shiono, MD, PhD, Masami Abiko,
More informationFrequencies of actionable mutations and survival in variants of invasive adenocarcinoma of lung
Original Article Frequencies of actionable mutations and survival in variants of invasive adenocarcinoma of lung Zhengbo Song 1,2 *, Tangfeng Lv 1 *, Yiping Zhang 2, Yong Song 1 1 Department of Respiratory
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationOriginal Article Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma
Int J Clin Exp Pathol 2014;7(11):8039-8045 www.ijcep.com /ISSN:1936-2625/IJCEP0002211 Original Article Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification
More informationLung cancer is the most common cause of cancer death in
ORIGINAL ARTICLE Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features? Catherine
More informationCAP Laboratory Improvement Programs. Worldwide Frequency of Commonly Detected EGFR Mutations
CAP Laboratory Improvement Programs Worldwide Frequency of Commonly Detected EGFR Mutations Rondell P. Graham, MBBS; Amanda L. Treece, MD; Neal I. Lindeman, MD; Patricia Vasalos, BS; Mu Shan, BS; Lawrence
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationEGFR Mutational Status of Primary Lung Adenocarcinoma in an Indian Cohort Based on 2015 WHO Classification of Lung tumors
Original Article DOI: 10.21276/APALM.1372 EGFR Mutational Status of Primary Lung Adenocarcinoma in an Indian Cohort Based on 2015 WHO Classification of Lung tumors Priyanka Yogendra Ravi 1 *, Anila Korula
More informationRead, Interpret, and Communicate Test Results
Read, Interpret, and Communicate Test Results Effective interpretation of epidermal growth factor receptor (EGFR) T790M mutation test results at progression will help physicians to set patient expectations
More informationFrequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung
HeSMO 6(2) 2015 19 23 DOI: 10.1515/fco-2015-0009 Forum of Clinical Oncology Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung Hanan Ezzat Shafik 1 *,
More informationNon-Small Cell Lung Carcinoma - Myers
Role of Routine Histology and Special Testing in Managing Patients with Non- Small Cell Lung Carcinoma Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of
More informationThe 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach
The 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach Dr. Carol Farver Director, Pulmonary Pathology Pathology and Laboratory Medicine Institute Objectives Discuss
More informationThe epidermal growth factor receptor (EGFR) is recognized as an important molecular target in cancer therapy. 1
Association of Diffuse, Random Pulmonary Metastases, Including Miliary Metastases, With Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma Yosuke Togashi, MD 1 ; Katsuhiro Masago, MD, PhD
More informationONCOLOGY LETTERS 8: , 2014
ONCOLOGY LETTERS 8: 813-818, 2014 Investigation of the epidermal growth factor receptor mutation rate in non small cell lung cancer patients and the analysis of associated risk factors using logistic regression
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationResearch Article Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma
BioMed Research International, Article ID 64568, 6 pages http://dx.doi.org/.55/24/64568 Research Article Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically
More informationSecond predominant subtype predicts outcomes of intermediatemalignant invasive lung adenocarcinoma
European Journal of Cardio-Thoracic Surgery 51 (2017) 218 222 doi:10.1093/ejcts/ezw318 Advance Access publication 6 October 2016 ORIGINAL ARTICLE Cite this article as: Ito M, Miyata Y, Yoshiya T, Tsutani
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationMOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE
25 th IAP-Arab Division Conference 07-09 November 2013, Amman, Jordan MOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE Fouad Al Dayel, MD, FRCPA, FRCPath Professor and Chairman Department
More informationThe histological grading of lung cancer is a significant
ORIGINAL ARTICLE Interobserver Agreement in the Nuclear Grading of Primary Pulmonary Adenocarcinoma Yoshimasa Nakazato, MD,* Akiko Miyagi Maeshima, MD, Yuichi Ishikawa, MD, Yasushi Yatabe, MD, Junya Fukuoka,
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationSurgical pathology of early stage non-small cell lung carcinoma
Review Article Page 1 of 8 Surgical pathology of early stage non-small cell lung carcinoma Mary Beth Beasley 1, Francine R. Dembitzer 1, Raja M. Flores 2 1 Department of Pathology, 2 Department of Thoracic
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationLung adenocarcinoma is the most common histologic
ORIGINAL ARTICLE Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations Analysis of 440 Japanese Patients Akihiko Yoshizawa,
More informationClinicopathologic Characteristics of EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC) in Central New York
North American Journal of Medicine and Science Jan 2018 Vol 11 No.1 1 Original Research Clinicopathologic Characteristics of EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC) in Central New York Daniel
More informationRetrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
More information8/22/2016. Major risk factors for the development of lung cancer are: Outline
Carcinomas of the Lung: Changes in Staging, Adenocarcinoma Classification and Genetics Grace Y. Lin, M.D., Ph.D. Outline Background Staging of Lung Cancer: Review of the 2010 7 th Edition of the AJCC Cancer
More informationThe lung adenocarcinoma guidelines: what to be considered by surgeons
Review Article The lung adenocarcinoma guidelines: what to be considered by surgeons Rodrigo A. S. Sardenberg 1, Evandro Sobroza Mello 1, Riad N. Younes 2 1 Hospital Alemão Oswaldo Cruz, São Paulo, Brazil;
More informationKey Words: Lung neoplasms; Receptor, epidermal growth factor; Mutation; Sequencing analysis, DNA; Peptide nucleic acids; Pyrosequencing
The Korean Journal of Pathology 2013; 47: 52-60 ORIGINAL ARTICLE Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationSOLITARY PULMONARY NODULES
SOLITARY PULMONARY NODULES Histological subtypes of solitary pulmonary nodules of adenocarcinoma and their clinical relevance Hui-Di Hu 1*, Ming-Yue Wan 1*, Chun-Hua Xu 2,3, Ping Zhan 2,3, Jue Zou 1, Qian-Qian
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationLung Neoplasia II Resection specimens Pathobasic. Lukas Bubendorf Pathology
Lung Neoplasia II Resection specimens Pathobasic Lukas Bubendorf Pathology Agenda Preneoplastic lesions Histological subtypes of lung cancer Histological patterns of AC Cells of origin and characteristic
More informationThe new international multidisciplinary lung adenocarcinoma
Eur Respir J 2011; 38: 239 243 DOI: 10.1183/09031936.00026711 CopyrightßERS 2011 EDITORIAL Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification W.D. Travis*,"",
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationLung cancer continues to be the leading cause of cancer
original article Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis? A Clinicopathologic Study of 176 Patients with Pathological Stage IA Lung Adenocarcinoma Based on the IASLC/ATS/ERS
More informationLi et al. BMC Genetics (2015) 16:20 DOI /s
Li et al. BMC Genetics (2015) 16:20 DOI 10.1186/s12863-015-0181-4 RESEARCH ARTICLE Open Access Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationUPDATES IN THE SURGICAL PATHOLOGY OF LUNG CANCER. Four Ps of Pulmonary Cytopathology: Procedural, Predictive, Personalized and Participatory
UPDATES IN THE SURGICAL PATHOLOGY OF LUNG CANCER travisw@mskcc.org Four Ps of Pulmonary Cytopathology: Procedural, Predictive, Personalized and Participatory American Society of Cytopathology Companion
More informationMutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma
Cancer Medicine ORIGINAL RESEARCH Open Access Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma Zhengbo Song 1,2, Xinmin Yu 1 & Yiping Zhang 1,2 1 Department
More informationMinor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis
Ann Surg Oncol (2016) 23:2099 2105 DOI 10.1245/s10434-015-5043-9 ORIGINAL ARTICLE THORACIC ONCOLOGY Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph
More informationThe expression of SALL4 is significantly associated with EGFR, but not KRAS or EML4-ALK mutations in lung cancer
Original Article The expression of SALL4 is significantly associated with EGFR, but not KRAS or EML4-ALK mutations in lung cancer Xiangbo Jia 1, Rulin Qian 2, Binbin Zhang 2, Song Zhao 1 1 Department of
More informationDiffering histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations
Original Article Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations Youngkyu Moon 1, Kyo Young Lee 2, Sook Whan Sung 1, Jae Kil Park 1 1 Department of
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationCytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics. Mercè Jordà, University of Miami
Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics Mercè Jordà, University of Miami Mortality Lung cancer is the most frequent cause of cancer incidence and mortality
More informationMolecular Diagnosis of Lung Cancer
Molecular Diagnosis of Lung Cancer Lucian R. Chirieac, M.D. Assistant Professor of Pathology Harvard Medical School Staff Pathologist, Department of Pathology Brigham and Women's Hospital 75 Francis Street
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationEGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE EGFR s in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China Can Pi 1,2*, Chong-Rui Xu 2*, Ming-feng Zhang
More informationRESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
More informationQuality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
More informationABSTRACT. PERMANYER. J Cancerol. 2015;2:56-63
www.journalofcancerology.com PERMANYER J Cancerol. 2015;2:56-63 JOURNAL OF CANCEROLOGY REVIEW ARTICLE Outcome of Patients with Lung Adenocarcinoma Harboring Common and Rare Epidermal Growth Factor Receptor
More informationANTICANCER RESEARCH 26: (2006)
Diffuse Micronodular Pulmonary Metastasis of Lung Adenocarcinoma Predicts Gefitinib Response in Association with Epidermal Growth Factor Receptor Mutations MAKOTO KOBAYASHI 1, TAMOTSU TAKEUCHI 2, KENTARO
More informationClassification of non-small cell lung carcinomas (NSCLC)
Classification of non-small cell lung carcinomas (NSCLC) 1. NordiQC Conference on Standardization in Applied Immunohistochemistry 4-7 June 2013 Birgit Guldhammer Skov, MD. DMeSci, Dept. Of Pathology, Rigshospitalet,
More informationNon-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Journal of Pathology and Translational Medicine 2016; 50: 197-203 ORIGINAL ARTICLE Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases Taebum
More informationShould minimally invasive lung adenocarcinoma be transferred from stage IA1 to stage 0 in future updates of the TNM staging system?
Original Article Should minimally invasive lung adenocarcinoma be transferred from stage to stage 0 in future updates of the TNM staging system? Tianxiang Chen 1,2#, Jizhuang Luo 3#, Haiyong Gu 3, Yu Gu
More informationLihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article
Original Article MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients Lihong Ma 1
More informationYan Zhang 1*, Zheng Wang 2*, Xuezhi Hao 1, Xingsheng Hu 1, Hongyu Wang 1, Yan Wang 1, Jianming Ying 3. Original Article. Abstract
Original Article Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations Yan Zhang
More informationand management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center
The new role of cytology in the diagnosis and management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center Outline Role of cytology in the diagnosis of lung cancer Non-small
More informationQuality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE:
More informationAn Interactive Guide to ALK+ Lymphoma. Our understanding of lung cancer has changed From one disease to many subtypes LCD
An Interactive Guide to ALK+ Anaplastic Lymphoma Kinase Non-Small Cell Lung (NSCLC) Our understanding of lung cancer has changed From one disease to many subtypes Click to get started Learning about Lung
More informationSUBJECT: GENOTYPING - EPIDERMAL GROWTH
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature
More informationUpdate on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationHistopathology of NSCLC, IHC markers and ptnm classification
ESMO Preceptorship on Non-Small Cell Lung Cancer November 15 th & 16 th 2017 Singapore Histopathology of NSCLC, IHC markers and ptnm classification Prof Keith M Kerr Department of Pathology, Aberdeen University
More informationA Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma
Jpn J Clin Oncol 26;36(2)69 75 doi:.93/jjco/hyi228 Original Articles A Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma Hiroshi
More informationLung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers
Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers The Harvard community has made this article openly available. Please share how this access
More informationEpidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Original Research
More informationPulmonary adenocarcinoma Issues, Issues and more issues. Why the headache?
Issues Pulmonary adenocarcinoma Issues, Issues and more issues. Why the headache? Classification Multiple nodules Invasive size Alain Borczuk, MD Weill Cornell Medicine Chronic headache - Classification
More informationYong Zhang 1#, Ling Ye 1#, Huijun Zhang 1, Xuehua Chen 1, Haiying Ji 1, Gang Chen 1, Lu Zhang 2, Tengfei Zhang 2, Meiling Jin 1.
Case Report A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors Yong Zhang 1#, Ling Ye 1#,
More informationThe discovery of targetable driver mutations in a subset of
Original Article Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers Anya M. Litvak, MD,* Paul K. Paik, MD,* Kaitlin M. Woo, MS, Camelia S. Sima, MD, Matthew D. Hellmann, MD,*
More informationKey Words. Lung cancer EGFR Mutation Genetic screening
The Oncologist Lung Cancer Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing LECIA V. SEQUIST, VICTORIA A. JOSHI, PASI A. JÄNNE, ALONA
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationMay 9, Dr. James Almas Medical Director MolDX 17 Technology Circle AG-315 Columbia, SC Dear Dr. Almas:
May 9, 2018 Dr. James Almas Medical Director MolDX 17 Technology Circle AG-315 Columbia, SC 29202 Dear Dr. Almas: On behalf of LUNGevity Foundation, the nation s preeminent lung cancer nonprofit that funds
More informationEpidermal growth factor receptor mutation and pattern of brain metastasis in patients with nonsmall cell lung cancer
ORIGINAL ARTICLE Korean J Intern Med 218;33:168-175 https://doi.org/1.394/kjim.215.158 Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with nonsmall cell lung cancer
More informationThe identification of epidermal growth factor receptor
Original Article Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 2 Insertions Geoffrey R. Oxnard, MD,* Peter C. Lo,* Mizuki Nishino, MD, Suzanne E. Dahlberg, PhD, Neal
More informationTest Category: Prognostic and Predictive. Clinical Scenario
Use of Epidermal Growth Factor Receptor (EGFR) Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) to Determine Erlotinib Use as First-line Therapy Test Category: Prognostic
More informationIASLC 2011/WHO 2015 CLASSIFICATION OF LUNG ADENOCARCINOMAS
Serban Negoita Dylan Holt Marsha Dunn IASLC 2011/WHO 2015 CLASSIFICATION OF LUNG ADENOCARCINOMAS DEMOGRAPHIC PATTERNS, TRENDS, AND IMPLICATIONS FOR CANCER SURVEILLANCE Outline Relevance of lung adenocarcinoma
More informationThere has been a growing interest in lung cancer in neversmokers,
ORIGINAL ARTICLE,, and Time of Diagnosis Are Important Factors for Prognosis Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan Tomoya Kawaguchi, MD,* Minoru Takada, MD,*
More informationAnalysis of the EGFR gene mutation in patients with nonsmall cell lung cancer in a Chinese population
Tropical Journal of Pharmaceutical Research August 2016; 15 (8): 1637-1641 ISSN: 1596-5996 (print); 1596-9827 (electronic) Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001
More informationRole of molecular studies in the diagnosis of lung adenocarcinoma
& 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 S11 Role of molecular studies in the diagnosis of lung adenocarcinoma Samuel A Yousem Department of Pathology, University of Pittsburgh Medical
More informationI appreciate the courtesy of Kusumoto at NCC for this presentation. What is Early Lung Cancers. Early Lung Cancers. Early Lung Cancers 18/10/55
I appreciate the courtesy of Kusumoto at NCC for this presentation. Dr. What is Early Lung Cancers DEATH Early period in its lifetime Curative period in its lifetime Early Lung Cancers Early Lung Cancers
More informationA nonresponding small cell lung cancer combined with adenocarcinoma
Case Report A nonresponding small cell lung cancer combined with adenocarcinoma Hongyang Lu 1,2, Shifeng Yang 3 1 Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung
More informationDirect serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis
ONCOLOGY REPORTS 28: 1815-1821, 2012 Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis CHENGJIN HU 1, XIAOLEI LIU 1, YINGJIAN CHEN 1, XIAOMING
More informationBiomedical Research 2017; 28 (14): ISSN X
Biomedical Research 2017; 28 (14): ISSN 0970-938X www.biomedres.info Study of the relationship between EGFR mutation status and bone metastasis in advanced lung adenocarcinoma. Xiaoye Ai, Adalati Yasheng,
More informationGround Glass Opacities
Ground Glass Opacities A pathologist s perspective Marie-Christine Aubry, M.D. Professor of Pathology Mayo Clinic Objectives Discuss the proposed new pathologic classification of adenocarcinoma with historical
More informationIntroduction: Overview of Current Status of Lung Cancer Predictive Biomarkers
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Program 7:15 7:40 Translocations as predictive biomarkers in lung cancer: Overview Mari Mino Kenudson, MD 7:40 8:05 Translocation
More informationLung cancer is the leading cause of cancer death worldwide.
ORIGINAL ARTICLE Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival
More informationDevelopment of a rapid and practical mutation screening assay for human lung adenocarcinoma
1900 Development of a rapid and practical mutation screening assay for human lung adenocarcinoma HELEN CHOI 1,2, JOHANNES KRATZ 1, PATRICK PHAM 1, SHARON LEE 1, ROSHNI RAY 1, YONG-WON KWON 3, JIAN-HUA
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationNon Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
More informationCorrelation in histological subtypes with high resolution computed tomography signatures of early stage lung adenocarcinoma
Original Article Correlation in histological subtypes with high resolution computed tomography signatures of early stage lung adenocarcinoma Yingying Miao 1,2 *, Jianya Zhang 1,2 *, Jiawei Zou 1,2, Qingqing
More informationGTS. Earn CME credits at
Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center Sandra P. D Angelo, MD, Bernard Park,
More information